Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 24, 2025 (GLOBE NE ...

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that securities class action lawsuit has been filed in the United States District Court for the District of Delaware on behalf of all persons or entities who purchased or otherwise acquired 3D Systems Corporation (3D Systems or the Company) (NYSE: DDD) securities between August 13, 2024 and May 12, 2025, inclusive (the Class Period). Investors who purchased or otherwise acquired shares of 3D Systems should contac ...

Core Viewpoint - UroGen Pharma Ltd. is facing a federal securities class action due to allegations of misleading statements regarding the effectiveness of its drug UGN-102, leading to significant stock price declines following negative FDA feedback and advisory committee decisions [4][5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against UroGen and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $75,000 in UroGen between July 27, 2023, and May 15, 2025, are encouraged to contact the firm for legal options [1]. - The court-appointed lead plaintiff will represent the interests of the class and any member can move to serve as lead plaintiff [7]. Group 2: Allegations Against UroGen - The complaint alleges that UroGen and its executives violated federal securities laws by making false statements and failing to disclose critical information about the ENVISION clinical study [4]. - Specific allegations include the study's lack of a concurrent control arm, which undermined the ability to demonstrate the drug's effectiveness, and the company's disregard for FDA warnings regarding study design [4]. - As a result of these issues, there was a substantial risk that the new drug application (NDA) for UGN-102 would not be approved, leading to misleading positive statements about the company's prospects [4]. Group 3: Stock Price Impact - Following the FDA's briefing document questioning the effectiveness of UGN-102, UroGen's stock price fell by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [5]. - After the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102, the stock price dropped by $3.37, or 44.7%, closing at $4.17 per share on May 21, 2025 [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant financial losses for investors [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Rocket securities between February 27, 2025, and May 26, 2025, with a deadline of August 11, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Rocket made positive statements while concealing serious risks, including the occurrence of Serious Adverse Events (SAEs) during clinical trials [3]. Clinical Trial Issues - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which is claimed to have misled investors about the safety of the treatment [3]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a SAE, which included death, following the undisclosed protocol amendment [4]. Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending to closed platforms, where the company's capabilities were limited [5]. - It is claimed that the monetization of DoubleVerify's high-margin Activation Services was hindered by the expensive and time-consuming development of technology for closed platforms [5]. - The complaint states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, negatively impacting the company's competitive edge and profits [5]. - Allegations include systematic overbilling of customers for ad impressions served to declared bots, which undermined the integrity of DoubleVerify's services [5]. - The company's risk disclosures were characterized as materially false and misleading, presenting adverse facts as mere possibilities [5]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a significant stock price drop of 36% following disappointing earnings and the suspension of services by a major customer [6]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [6]. Group 3: Legal Proceedings - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is also typical of class members, overseeing the litigation on behalf of the class [7]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fortrea To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Red Cat To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) between February 27, 2025, to May 26, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Rondolph Ho v. Rocket Pharmaceuticals, Inc., et al. (Case No. 3:25-cv-10049) has been commenced in the United States District Court ...

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- June 11, 2025 - Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares of PepGen should contact the Firm prior to the August 8, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO J ...